A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Rilzabrutinib (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Therapeutic Use
- Acronyms wAIHA
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 25 Jul 2024 According to a Sanofi media release, data form this trial is expected in second half of 2024.
- 18 May 2024 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 13 Mar 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.